Журнал кардиореспираторных исследований 2025. №2

Тема статьи

PODАGRА KАSАLLIGIDА METАBOLIK SINDROM VА KАRDIАL ZАRАRLАNISH XАVF OMILLАRI XUSUSIYATLАRINI YOSHGA BOG’LIQ HOLDA O’RGANISH (54-58)

Авторы

Tairov Doston Rustamovich

Учреждение

Samarqanda Davlat Tibbiyot Universiteti

Аннотация

Bizning tekshiruvlarimizda podagra kasalligi bilan kasallangan jami 54 nafar bemorni o’rgandik. Ularning orasida arterial gipertoniya bilan kasallangan bemorlar bemorlarning 36 nafarida (72%) kuzatildi. Tekshiruvimizda bemorlar podagra kasalligining kechishiga ko’ra 2 ta katta guruhga bo'lib o'rganildi: kasallik qaytalanib kechgan bemorlar I-guruh (n=27) va kasallik surunkali kechgan bemorlar II- guruh (n=23). Ikkala guruhlarda bemorlarning kardiovaskulyar zararlanishlari uchrash chastotasi va xarakterli belgilari, bo’g’im sindromi o'rganildi. Podagra bilan kasallangan bemorlarda bo'g'im sindromini arterial gipertoniya, yurak ishemik kasalligi va surunkali yurak yetishmovchiligi bilan qiyosiy tahlil o'tkazildi. Podagra bilan kasallangan arterial gipertoniya, yurak ishemik kasalligi va surunkali yurak yetishmovchiligi mavjud bo'lgan bemorlarda zararlangan bo'g'imlar soni va kasallikning og'irlik indeksi ham ushbu kasalliklari mavjud bo'lmagan bemorlarga qaraganda yuqoriligi aniqlandi. Podagra kasalligi bilan kasallangan bemorlarda yosh ko’rsatkichiga bog’liq holda podagra kasalligidagi bo‘g‘im sindromi va kardiovaskulyar zararlanishlarning qiyosiy tahlil qilish.

Ключевые слова

surunkali yurak yetishmovchiligi, artrit, arterial gipertenziya, yurak ishemik kasalligi, xolesterin, qandli diabet.

Литературы

1. Tairov D.R., Berdiev D.KH. "Gout: Immunological and genetic characteristics of the disease." Volume: 3, Issue: 12, Dec- 2024. journals.academiczone.net. 2. Tairov D.R., Berdiev D.KH. "Characteristics of Cardiohemodynamic Disorders in Gout Disease." SCIENTIFIC PROGRESS. Volume 2, Issue 3, 2021. ISSN: 2181-1601. 3. Tairov D.R., Berdiev D.KH. "Medication and Non-Medication Methods to Eliminate Hyperuricemia in Gout." "Science and Education" Scientific Journal. Impact Factor 3.848. May 2023, Volume 4, Issue 5. 4. Tairov D.R., Berdiev D.KH. "Characteristics of Heart Functional Disorders in Gout Disease." GALAXY INTERNATIONAL INTERDISCIPLINARY RESEARCH JOURNAL (GIIRJ). ISSN (E): 2347-6915. Vol. 10, Issue 5, May 2022. 5. Tairov D.R., Berdiev D.KH. "Cardiovascular Damage and Metabolic Syndrome Comorbidities in Patients with Gout Disease." 2nd International Congress on Multidisciplinary Studies. Indonesia. February 20th, 2021. conferencepublication.com. 6. Nasonov E.L., Karateev D.E., Satibaldiyev A.M., et al. (2015). 7. Adams P.F. "Current Estimates from the National Health Interview Survey, 1996." Vital Health Stat. Vol. 10, 1999. 8. Saag K.G., Mikuls T.R. "Recent Advances in the Epidemiology of Gout." Curr. Rheumatol. Rep. Vol. 7, 2005, pp. 235–241. 9. Terkeltaub R.A. "Clinical Practice. Gout." N. Engl. J. Med. Vol. 349, 2003, pp. 1647–1655. 10. Tairov E.S., Tairov D.R. "Metabolic Syndrome in Gout: Its Relationship with Renal Functional Disorders." Questions of Science and Education. No. 28 (77), 2019. 11. Wallace K.L., Riedel A.A., Joseph-Ridge N. "Increasing Prevalence of Gout and Hyperuricemia Over 10 Years Among Older Adults in a Managed Care Population." J. Rheumatol. Vol. 31, 2004, pp. 1582–1587. 12. Tairov D.R., Makhmudova H.D. "Cardiovascular Damage in Patients with Gout." Scientific Progress. Vol. 2, No. 2, 2021, pp. 242–249. 13. Yarmukhamedova S.KH., Kamolova D.ZH. "Study of Myocardial Geometry in Hypertensive Patients Using Echocardiography." Achievements of Science and Education. No. 12 (53), 2019. 14. Eliseev M.S., Barskova V.G., Nasonov V.A. "Clinical Significance of Metabolic Syndrome in Gout." Clinical Gerontology. Vol. 12, No. 2, 2006, pp. 29–33. 15. Tairov E.S., Tairov D.R., Solovyev S.K. "Gout: Diagnosis and Treatment." Tashkent, Uzbekistan, 2020. 16. Sowers M.J., Whaley-Connell A., Hayden M.R. "The Role of Obesity in Cardiorenal Syndrome." Cardiorenal Medicine. Vol. 1, 2011, pp. 5–12. 17. Hayden M., Tyagi S.K. "Uric Acid: A New Perspective on an Old Cardiovascular Risk Marker." Nutr Metab (London). Vol. 1, 2004, p. 10. 18. Jalal D.I., Chonchol M., Chen W., Targher G. "Uric Acid as a Therapeutic Target in CKD." Am J. Dis., 2013, Vol. 61, pp. 134–146. 19. Johnson R.J., Segal M.S., Sautin Y., Nakagawa T., Feig D.I., Kang D.H., Gersch M.S., Benner S., Sanchez-Lozada L.G. "Potential Role of Sugar (Fructose) in the Epidemics of Hypertension, Obesity, and Metabolic Syndrome." Am J Clin Nutr. Vol. 86, 2007, pp. 899–906. 20. Steele T. "Human Urate Secretion: Pyrazinamide Suppression Test." Ann Intern Med. Vol. 79, 1973, pp. 734–737. 21. Suliman M.E., Johnson R.J., Garcia-Lopez E., et al. "J-Shaped Relationship Between Uric Acid and Mortality in CKD." Am J. Dis. Vol. 48, 2006, pp. 761–771. 22. Kan D.H., Nakagawa T., Feng L., Watanabe S., Han L., Mazzali M., Truong L., Harris R., Johnson R.J. "The Role of Uric Acid in Kidney Disease Progression." J Am Soc Nephrol. Vol. 13, 2002, pp. 2888–2897. 23. Tseng C. "Correlation of Urinary Albumin Excretion Rate with Uric Acid Levels in Type 2 Diabetes." Kidney Int. Vol. 68, 2005, pp. 796–801. 24. Ono I., Hosoya T., Gomi H., et al. "Serum Uric Acid and Kidney Failure Prognosis in IgA Nephropathy Patients." Nephron. Vol. 87, 2001, pp. 333–339. 25. Thomas G., Sehgal A.R., Kashyap S.R., Srinivas T.R., et al. "Metabolic Syndrome and Kidney Disease: A Systematic Review and Meta-Analysis." Clin J Am Soc Nephrol. Vol. 6, 2011, pp. 2364–2373. 26. Wright A.F., Rudan I., Hastie N.D., Campbell H. "The Complexity of Urate Transporters." Kidney Int. Vol. 78, 2010, pp. 446–452. 27. Gutman A.B., Yu T.F. "Urate Nephrolithiasis." Am J Med. Vol. 45, 1968, pp. 756–779.